Eli Lilly's press release — LLY's reaction is being measured

LLY's realized reaction is still being measured.

· PR Newswire · Press release · Realized reaction, point-in-time, zero look-ahead.

Source headline

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Via PR Newswire

How LLY reacted

Reaction is being measured.

This event is recent. News Quantified labels the realized price reaction once the trading sessions after the news complete — point-in-time, with zero look-ahead. The measured move will appear here, and below in LLY’s reaction history.

What happened

Where this LLY event came from, and what the tape did with it.

Eli Lilly issued a press release, carried via PR Newswire, on Oct 18, 2026. It was the only Eli Lilly headline News Quantified labeled that day.

Against the price at the news timestamp, LLY's reaction is still being measured.

Context

How this compares to LLY’s usual reaction.

Across 2,000+ labeled events, LLY’s median 30-minute reaction to all news is +0.03% (52% up); by the close it is -0.07%.

Where this LLY event landedvs 2,000+ measured LLY reactions
LLYMiddle 50% · -0.57% to +0.60%Zero: 0.00%Median: +0.03%Median +0.03%-1.00%0+1.00%
Middle 50% of LLY reactions-0.57% to +0.60%
Median reaction (30-min)+0.03%
Measured reactions2,000+
Point-in-time · zero look-ahead

Half of all Eli Lilly news events land between -0.57% and +0.60% at 30 minutes; this one is a single draw from that distribution.

That’s the median — get an email the next time LLY moves on news →

You just saw one reaction. There are 26M+ more.

See the full LLY reaction history →
Next time, know first

Email me when LLY moves on news.

One email per qualifying move — the headline, the measured reaction, and how it compares to LLY's baseline. Nothing else.

▲ LLY Free · unsubscribe anytime
26M+ news records Operating since 2012 Methodology on SSRN ↗
Similar LLY events

How comparable LLY events have landed.

Across 5 other recent Eli Lilly press release events, the median close-day reaction was -0.39%. Each is measured the same way, from its own news timestamp.

Go deeper

8 more LLY events, each measured the same way.

Recent LLY events, each with its measured reaction8
DateHeadline5-minTo close
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease-0.65%-0.31%
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes+0.59%-2.88%
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study-0.65%-0.31%
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis+0.06%-2.48%
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison+0.34%+0.15%
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes+0.06%-2.48%
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison+0.34%+0.15%
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs+0.69%+0.39%
That same day, across the market1

Same measurement, same clock, different names — each headline measured from its own news timestamp, point-in-time.

Peer tickers, measured the same way4
Method

How the numbers are made.

How was LLY's 5-minute reaction measured?

From the news timestamp, not the trading day: News Quantified takes the last trade before this press release as the base price and measures the move five minutes of trading later — point-in-time, zero look-ahead. The same clock produced the to-close figure.

What is Eli Lilly's median reaction, and how does this event compare?

Eli Lilly's median is drawn from 2,000+ labeled events; at 30 minutes it sits at +0.03%, and -0.07% by the close. This event's move is one draw from that distribution — ordinary or outlier, the chart's median ticks show which.

Only one Eli Lilly headline was labeled Oct 18, 2026. How is it isolated?

It was the only Eli Lilly headline labeled that day, so its window has no same-day overlap — the move is measured cleanly from its own timestamp.

Does a measured reaction predict Eli Lilly's next reaction?

No. a measured reaction is a realized fact about Oct 18, 2026, not a forecast. Past reactions describe a distribution; they say nothing certain about any future move.

Cite this data

How to cite this reaction.

News Quantified. "Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress." LLY realized price reaction, Oct 18, 2026. Retrieved from https://newsquantified.com/tickers/lly/news/lilly-showcase-advances-across-its-oncology-pipeline-2026-2026-10-18

Canonical URL: https://newsquantified.com/tickers/lly/news/lilly-showcase-advances-across-its-oncology-pipeline-2026-2026-10-18

Query this dataset via the API & MCP →
Stop guessing what the event means

You just saw one reaction.
There are 26 million more.

For investors

Know the next move, measured.

Ticker alerts with the realized reaction — not the headline spin.

Free · no credit card · unsubscribe anytime
For builders

The dataset, one command away.

claude mcp add news-quantified

Then ask Claude: “how does LLY react to downgrades?” — or pull it raw via REST.

60-second signup on the NQ portal · 100 free credits/mo
26M+ news records, 2006–2026 Operating since 2012 Point-in-time, zero look-ahead Peer-reviewable methodology (SSRN) ↗